Abpro Holdings, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Abpro Holdings, Inc. has received final notification from the Nasdaq Listing and Hearing Review Council that its securities will be delisted for failure to meet minimum equity requirements.
Abpro Holdings, Inc. received multiple Nasdaq non-compliance notices regarding board and committee independence, prompting director appointments amid delisting concerns.
Abpro Holdings, Inc. secured a $147,000 unsecured loan from its CEO to cover D&O insurance premiums and appointed Dr. Byung-Hak Yoon to its Board of Directors.
Abpro Holdings, Inc. and Celltrion, Inc. announced FDA Investigational New Drug (IND) clearance for their lead multispecific antibody oncology program, ABP-102 / CT-P72, enabling a Phase 1 clinical trial.
Abpro Holdings and Celltrion submitted an Investigational New Drug application to the FDA for ABP-102/CT-P72, a T cell engager for HER2-positive cancers.
Abpro Holdings, Inc. received a Nasdaq extension to regain listing compliance, citing progress on its turnaround strategy and pipeline advancement.
Abpro and Celltrion announced new preclinical data for their bispecific antibody CT-P72/ABP-102, demonstrating potent anti-tumor activity in HER2-high and Enhertu-resistant models with a favorable safety profile, supporting its clinical advancement.
Abpro and Celltrion announced new preclinical data for their HER2CD3 T-cell engager, CT-P72/ABP-102, showing potent anti-tumor activity and a favorable safety profile, advancing it towards clinical trials.
Abpro Holdings, Inc. announced the effectiveness of a 1-for-30 reverse stock split to maintain Nasdaq listing compliance, alongside a 60% reduction in operating costs.
Abpro Holdings, Inc. will implement a 1-for-30 reverse stock split, effective October 31, 2025, to consolidate its common stock.
Abpro Holdings, Inc. received a notice of non-compliance with Nasdaq's minimum MVPHS and MVLS requirements, with a delisting hearing scheduled for October 30, 2025.
Abpro Holdings' stockholders approved a 1-for-30 reverse stock split and re-elected a director at their 2025 annual meeting.
Abpro Holdings, Inc. received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement, but plans to appeal.
Abpro Holdings, Inc. announced the furlough and subsequent termination of its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr.
Abpro Holdings, Inc. entered into a consulting agreement with BioCelsus International Inc., an entity wholly owned by CEO Jin Wook (Miles) Suk, outlining compensation and significant change of control provisions.
Abpro Holdings, Inc. announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 17, 2025, to an undetermined future date.
8-K: Abpro and Celltrion Unveil Promising Preclinical Data for Cancer Therapy ABP-102/CT-P72 at AACR 2025
Abpro and Celltrion presented preclinical data at AACR 2025 for ABP-102/CT-P72, a potential best-in-class HER2 x CD3 T-cell engager, showing superior tumor selectivity, potent efficacy, and an improved safety profile.
8-K: Abpro Holdings Amends Convertible Promissory Note with YA II PN, LTD to Correct Scrivener's Error
Abpro Holdings, Inc. amended its Convertible Promissory Note with YA II PN, LTD to correct a scrivener's error in the definition of the Conversion Price.
Abpro Holdings, Inc. received notifications from Nasdaq regarding non-compliance with minimum Market Value of Publicly Held Shares (MVPHS) and Market Value of Listed Securities (MVLS) requirements.
Abpro Holdings, Inc. announced that its prior financial statements for the periods ended September 30, 2024, December 31, 2023, and December 31, 2022, should no longer be relied upon due to an understatement of liabilities under a license agreement.
Abpro Holdings, Inc. announces stockholder approval for the issuance of common stock to Yorkville, potentially exceeding 20% of outstanding shares, under the Standby Equity Purchase Agreement.
Abpro Holdings, Inc. received a notice from Nasdaq for failing to meet the minimum bid price requirement for continued listing.
Abpro Holdings, Inc. will present preclinical data for its bispecific T-cell engager, ABP-102/CT-P72, at the American Association for Cancer Research Annual Meeting 2025.
Abpro Holdings, Inc. has terminated Ian Chan as Chief Executive Officer, effective March 3, 2025.
Abpro Holdings adjusts its warrant price to $3.83 and redemption trigger to $5.99 due to the issuance of common stock and securities at $3.33 per share during its business combination.
Abpro Holdings, Inc. released an investor presentation outlining its pipeline of antibody therapies and strategic partnerships, including a significant collaboration with Celltrion.
Abpro Holdings, a biotech company, celebrated the closing of its business combination with Atlantic Coastal Acquisition Corp II with a Nasdaq bell ringing ceremony and announced several financing agreements to support its pipeline.
Abpro Holdings, Inc. has dismissed Marcum LLP as its independent auditor and engaged Wolf & Company, P.C. effective December 9, 2024.
Abpro Holdings, Inc. announces the resignation of its Chief Financial Officer, Shahraab Ahmad, effective November 22, 2024.
Abpro Holdings, Inc. has announced a new equity incentive plan aimed at attracting and retaining key personnel by offering equity interests and incentive compensation tied to company performance.